The company is voluntarily recalling product because of glass particles found in vials.
On Jan. 3, 2018, AuroMedics Pharma LLC announced it was voluntarily recalling lot AFO l 17001-A of Ampicillin and Sulbactam for Injection USP, 1.5 g (equivalent to 1 g ampicillin as the sodium salt plus 0.5 g Sulbactam as the sodium salt) in a Single-Dose vial, to the hospital level. The product is being recalled after glass particulates were found in vials.
According to the company, if glass is present in the intravenous drug and is administered, reactions from local irritation and swelling to more serious conditions such as blockage and clotting in blood vessels may occur. No adverse events have been reported as of January 3.
The affected lot has an expiration date of December 2018 and is packaged in a carton containing 10 vials, NDC: 55150-116-20. The lot was shipped to wholesalers and/or hospitals nationwide on Feb. 9, 2017.
Ampicillin and Sulbactam for Injection is used to treat infections “due to susceptible strains of designated microorganism in skin and skin structure infections, intraÂabdominal infections, and gynecological infections in adults and for treatment of skin and skin structure infection in pediatric patient one year and older,” according to a press release.
Source: FDA
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.